Appointments at GlaxoSmithKline, Synthon, BioSante and Xencor – People on the move
GlaxoSmithKline (GSK) has appointed Philippe Fauchet as president of its operations in Japan. Fauchet joins GSK from Sanofi-Aventis where he worked since 1996, leading its Japanese business for four years.
Rudy Mareel has been appointed as CEO of Synthon. Before joining Synthon Mareel was a member of the executive leadership team at Cardinal Health. He has also worked at Royal Numico, Abbott Diagnostics and Becton Dickinson.
IDEA AG has named Gosse Bruinsma as CEO after Gregor Cevc, who founded the company in 1993, resigned with immediate effect. Cevc and the board had differing views on the company’s strategic direction, according to a release from IDEA.
Robert Phelps has joined SuppreMol as head of business development and licensing. Phelps previously held a similar position at PARI Pharma and has also worked at Nordic A/S, Patheon and Evotec AG.
Adeona Pharmaceuticals has promoted James Kuo to the positions of chairman, CEO and president. Kuo joined Adeona in 2007 having previously worked at Cordex Pharma, BioMicro Systems and Monarch Labs.
Jeffrey Winkelman has been appointed as vice president (VP), oncology programs at BioSante Pharmaceuticals. Winkelman has more than 15 years experience handling clinical development, intellectual property and licensing matters at companies including Cell Genesys.
Xencor has named Edgardo Baracchini as its chief business officer. Most recently Baracchini worked at Metabasis, leaving after the 2009 merger with Ligand Pharmaceuticals, and he has also held positions at Elitra Pharmaceuticals and Agouron Pharmaceuticals.
Jonathan Knowles has joined Lonza as a part-time scientific advisor. Knowles is a former member of the Roche executive committee and head of group research. In his new role he will mainly support the Lonza Innovation for Future Technologies (LIFT) initiative.
